Chief Business Officer · ENANTA PHARMACEUTICALS INC (ENTA)

Brendan Luu

A named executive officer of ENANTA PHARMACEUTICALS in every fiscal year CompBrief holds from FY2021 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$2,577,672

Salary $436,075Stock awards $1,034,100

FY2022: $2,313,568

4th of 6 named executive officers at Enanta Pharmaceuticals by FY2023 total.

6 named officers on file for ENANTA PHARMACEUTICALS, FY2023

Brendan Luu’s pay file — $29

  • 3 fiscal years of pay, line by line
  • 3 equity grants, each cited to its filing
  • ENTA’s disclosed peer group of 21 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how ENANTA PHARMACEUTICALS’s whole pay program stands against its peers

  • ENANTA PHARMACEUTICALS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ENTA→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed January 26, 2024 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Brendan Luu’s full pay file as a PDF — free

More than this page: up to 10 years of Brendan’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Brendan Luu compensation by year

ENANTA PHARMACEUTICALS Summary Compensation Table · all 3 fiscal years held
In US dollars, as ENANTA PHARMACEUTICALS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2021FY2022FY2023
Salary$254,795$411,300$436,075
Bonus$75,000$0$0
Stock awards$296,203$739,664$1,034,100
Option awards$1,757,805$985,114$920,716
Non-equity incentive$119,813$158,066$166,183
Pension and deferred compensation$0$0$0
All other$1,350$19,424$20,598
Total$2,504,966$2,313,568$2,577,672

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ENANTA PHARMACEUTICALS INC DEF 14A filed January 26, 2024, accession 0000950170-24-007956, and prior-year filings. Open the filing on EDGAR.

How this page was built: the ENANTA PHARMACEUTICALS INC filed document, accession 0000950170-24-007956. Every figure is read from that document and cited to the page and table it appears in. Filed January 26, 2024.

$2.5M
$2.3M
$2.6M
FY21
FY22
FY23
SalaryBonusNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
RSU18,500$206,645—
RSU5,100$56,967—
PSU5,000$55,850—
PSU5,000$55,850—
PSU4,150$46,356—
PSU4,150$46,356—
Option28,125—$48.03
Option15,975—$75.33
Option32,500—$45.00

Per the Outstanding Equity Awards at Fiscal Year-End table in ENANTA PHARMACEUTICALS INC's FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

13 Form 4 lines since the FY2023 proxy (filed January 26, 2024)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-02-12Tax withholding—3,257$14.2541,634
2026-02-12Grant or award—1,575$0.0039,904
2026-02-12Grant or award—4,987$0.0044,891
2025-12-05Sale—1,394$14.2338,329
2025-12-01Tax withholding—498$14.1239,723
2025-11-25Grant or award derivative—90,000$0.0090,000
2025-02-12Tax withholding—3,326$5.5940,221
2025-02-12Grant or award—7,500$0.0043,547

The 8 most recent of 13 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

ENANTA PHARMACEUTICALS’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Jay LulyPresident and Chief Executive Officer$7,856,698
Nathaniel GardinerChief Legal Officer and Corporate Secretary$2,855,081
Paul MellettChief Financial and Administrative Officer$2,849,250
Brendan Luu · this pageChief Business Officer$2,577,672
Yat Sun OrChief Scientific Officer$2,469,600
Scott RottinghausChief Medical Officer$1,654,724

The full ENANTA PHARMACEUTICALS compensation record

free company brief

This page is one person within ENANTA PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the ENANTA PHARMACEUTICALS proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are ENANTA PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Brendan Luu's compensation dossier · One-time report. No refunds.